139 related articles for article (PubMed ID: 34844106)
1. Empagliflozin adjunct with metformin for the inhibition of hepatocellular carcinoma progression: Emerging approach for new application.
Abdelhamid AM; Saber S; Youssef ME; Gaafar AGA; Eissa H; Abd-Eldayem MA; Alqarni M; Batiha GE; Obaidullah AJ; Shahien MA; El-Ahwany E; Amin NA; Etman MA; Kaddah MMY; Abd El-Fattah EE
Biomed Pharmacother; 2022 Jan; 145():112455. PubMed ID: 34844106
[TBL] [Abstract][Full Text] [Related]
2. Blunting p38 MAPKα and ERK1/2 activities by empagliflozin enhances the antifibrotic effect of metformin and augments its AMPK-induced NF-κB inactivation in mice intoxicated with carbon tetrachloride.
Abdelhamid AM; Youssef ME; Abd El-Fattah EE; Gobba NA; Gaafar AGA; Girgis S; Shata A; Hafez AM; El-Ahwany E; Amin NA; Shahien MA; Abd-Eldayem MA; Abou-Elrous M; Saber S
Life Sci; 2021 Dec; 286():120070. PubMed ID: 34688695
[TBL] [Abstract][Full Text] [Related]
3. Prognostic significance of AMPK activation and therapeutic effects of metformin in hepatocellular carcinoma.
Zheng L; Yang W; Wu F; Wang C; Yu L; Tang L; Qiu B; Li Y; Guo L; Wu M; Feng G; Zou D; Wang H
Clin Cancer Res; 2013 Oct; 19(19):5372-80. PubMed ID: 23942093
[TBL] [Abstract][Full Text] [Related]
4. Novel complementary antitumour effects of celastrol and metformin by targeting IκBκB, apoptosis and NLRP3 inflammasome activation in diethylnitrosamine-induced murine hepatocarcinogenesis.
Saber S; Ghanim AMH; El-Ahwany E; El-Kader EMA
Cancer Chemother Pharmacol; 2020 Feb; 85(2):331-343. PubMed ID: 31989218
[TBL] [Abstract][Full Text] [Related]
5. Metformin inhibits the invasion of human hepatocellular carcinoma cells and enhances the chemosensitivity to sorafenib through a downregulation of the ERK/JNK-mediated NF-κB-dependent pathway that reduces uPA and MMP-9 expression.
Hsieh SC; Tsai JP; Yang SF; Tang MJ; Hsieh YH
Amino Acids; 2014 Dec; 46(12):2809-22. PubMed ID: 25245054
[TBL] [Abstract][Full Text] [Related]
6. The SGLT2 inhibitor empagliflozin negatively regulates IL-17/IL-23 axis-mediated inflammatory responses in T2DM with NAFLD via the AMPK/mTOR/autophagy pathway.
Meng Z; Liu X; Li T; Fang T; Cheng Y; Han L; Sun B; Chen L
Int Immunopharmacol; 2021 May; 94():107492. PubMed ID: 33647823
[TBL] [Abstract][Full Text] [Related]
7. SGLT2-i improves markers of islet endothelial cell function in db/db diabetic mice.
Hogan MF; Hackney DJ; Aplin AC; Mundinger TO; Larmore MJ; Castillo JJ; Esser N; Zraika S; Hull RL
J Endocrinol; 2021 Feb; 248(2):95-106. PubMed ID: 33337344
[TBL] [Abstract][Full Text] [Related]
8. Low-dose metformin suppresses hepatocellular carcinoma metastasis via the AMPK/JNK/IL-8 pathway.
Zhao C; Zheng L; Ma Y; Zhang Y; Yue C; Gu F; Niu G; Chen Y
Int J Immunopathol Pharmacol; 2024; 38():3946320241249445. PubMed ID: 38679570
[TBL] [Abstract][Full Text] [Related]
9. Therapy of empagliflozin plus metformin on T2DM mice shows no higher amelioration for glucose and lipid metabolism than empagliflozin monotherapy.
Wang Z; Zhou J; Lu M; Liang Y; Jiang Z; Chen K
Life Sci; 2019 Sep; 232():116622. PubMed ID: 31271767
[TBL] [Abstract][Full Text] [Related]
10. SGLT2 inhibition with empagliflozin attenuates myocardial oxidative stress and fibrosis in diabetic mice heart.
Li C; Zhang J; Xue M; Li X; Han F; Liu X; Xu L; Lu Y; Cheng Y; Li T; Yu X; Sun B; Chen L
Cardiovasc Diabetol; 2019 Feb; 18(1):15. PubMed ID: 30710997
[TBL] [Abstract][Full Text] [Related]
11. SGLT2 Inhibitor Empagliflozin and DPP4 Inhibitor Linagliptin Reactivate Glomerular Autophagy in
Korbut AI; Taskaeva IS; Bgatova NP; Muraleva NA; Orlov NB; Dashkin MV; Khotskina AS; Zavyalov EL; Konenkov VI; Klein T; Klimontov VV
Int J Mol Sci; 2020 Apr; 21(8):. PubMed ID: 32340263
[TBL] [Abstract][Full Text] [Related]
12. Metformin promotes apoptosis in hepatocellular carcinoma through the CEBPD-induced autophagy pathway.
Tsai HH; Lai HY; Chen YC; Li CF; Huang HS; Liu HS; Tsai YS; Wang JM
Oncotarget; 2017 Feb; 8(8):13832-13845. PubMed ID: 28099155
[TBL] [Abstract][Full Text] [Related]
13. Low concentration of metformin induces a p53-dependent senescence in hepatoma cells via activation of the AMPK pathway.
Yi G; He Z; Zhou X; Xian L; Yuan T; Jia X; Hong J; He L; Liu J
Int J Oncol; 2013 Nov; 43(5):1503-10. PubMed ID: 23982736
[TBL] [Abstract][Full Text] [Related]
14. Metformin inhibits angiogenesis induced by interaction of hepatocellular carcinoma with hepatic stellate cells.
Qu H; Yang X
Cell Biochem Biophys; 2015 Mar; 71(2):931-6. PubMed ID: 25326336
[TBL] [Abstract][Full Text] [Related]
15. Empagliflozin and Liraglutide Differentially Modulate Cardiac Metabolism in Diabetic Cardiomyopathy in Rats.
Trang NN; Chung CC; Lee TW; Cheng WL; Kao YH; Huang SY; Lee TI; Chen YJ
Int J Mol Sci; 2021 Jan; 22(3):. PubMed ID: 33503985
[TBL] [Abstract][Full Text] [Related]
16. Empagliflozin protects heart from inflammation and energy depletion via AMPK activation.
Koyani CN; Plastira I; Sourij H; Hallström S; Schmidt A; Rainer PP; Bugger H; Frank S; Malle E; von Lewinski D
Pharmacol Res; 2020 Aug; 158():104870. PubMed ID: 32434052
[TBL] [Abstract][Full Text] [Related]
17. Empagliflozin reduces the levels of CD36 and cardiotoxic lipids while improving autophagy in the hearts of Zucker diabetic fatty rats.
Aragón-Herrera A; Feijóo-Bandín S; Otero Santiago M; Barral L; Campos-Toimil M; Gil-Longo J; Costa Pereira TM; García-Caballero T; Rodríguez-Segade S; Rodríguez J; Tarazón E; Roselló-Lletí E; Portolés M; Gualillo O; González-Juanatey JR; Lago F
Biochem Pharmacol; 2019 Dec; 170():113677. PubMed ID: 31647926
[TBL] [Abstract][Full Text] [Related]
18. Glycemic control with empagliflozin, a novel selective SGLT2 inhibitor, ameliorates cardiovascular injury and cognitive dysfunction in obese and type 2 diabetic mice.
Lin B; Koibuchi N; Hasegawa Y; Sueta D; Toyama K; Uekawa K; Ma M; Nakagawa T; Kusaka H; Kim-Mitsuyama S
Cardiovasc Diabetol; 2014 Oct; 13():148. PubMed ID: 25344694
[TBL] [Abstract][Full Text] [Related]
19. Empagliflozin improves left ventricular diastolic function of db/db mice.
Moellmann J; Klinkhammer BM; Droste P; Kappel B; Haj-Yehia E; Maxeiner S; Artati A; Adamski J; Boor P; Schütt K; Lopaschuk GD; Verma S; Marx N; Lehrke M
Biochim Biophys Acta Mol Basis Dis; 2020 Aug; 1866(8):165807. PubMed ID: 32353614
[TBL] [Abstract][Full Text] [Related]
20. Asarone and metformin delays experimentally induced hepatocellular carcinoma in diabetic milieu.
Das BK; Choukimath SM; Gadad PC
Life Sci; 2019 Aug; 230():10-18. PubMed ID: 31121175
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
